GlassScriptPhysician profile
Melissa Diane Larson
NPI 1972050961
$5,451.12
in general payments reported to CMS, 2019-2025
35 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.87 · 2020: $316 · 2021: $412 · 2022: $603 · 2023: $1,209 · 2024: $1,555 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,408.86 | 2021-2025 | |
| Novo Nordisk INC | $482.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $419.59 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $416.39 | 2020-2025 | |
| Lilly USA, LLC | $342.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Axsome Therapeutics, INC. | $222.66 | 2024-2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $207.52 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $204.53 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $200.22 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $195.58 | 2024-2025 | Fanapt, Hetlioz |
| Amgen INC. | $164.24 | 2021-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $154.76 | 2022-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $143.53 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.07 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.84 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $78.76 | 2024-2025 | Ingrezza |
| Astellas Pharma US INC | $68.21 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $60.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $53.06 | 2023-2025 | |
| Beta Bionics, INC. | $46.80 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Shield Therapeutics INC | $41.57 | 2024 | |
| Allergan, INC. | $40.74 | 2020 | |
| Janssen Pharmaceuticals, INC | $39.64 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.64 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $27.22 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $19.54 | 2020 | |
| Lundbeck LLC | $18.75 | 2025 | Rexulti |
| Amarin Pharma, INC. | $18.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.22 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $13.25 | 2023 | Prehevbrio |
| Teva Pharmaceuticals USA, INC. | $13.22 | 2023 | Airduo Digihaler |
| Sanofi-Aventis U.S. LLC | $12.65 | 2021 | |
| Sanofi Pasteur INC. | $12.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.